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Abstract
The histopathological evaluation of morphological features in breast tumours provides prognostic 
information to guide therapy. Adjunct molecular analyses provide further diagnostic, prognostic 
and predictive information. However, there is limited knowledge of the molecular basis of 
morphological phenotypes in invasive breast cancer. This study integrated genomic, transcriptomic 
and protein data to provide a comprehensive molecular profiling of morphological features in 
breast cancer. Fifteen pathologists assessed 850 invasive breast cancer cases from The Cancer 
Genome Atlas (TCGA). Morphological features were significantly associated with genomic 
alteration, DNA methylation subtype, PAM50 and microRNA subtypes, proliferation scores, gene 
expression and/or reverse-phase protein assay subtype. Marked nuclear pleomorphism, necrosis, 
inflammation and a high mitotic count were associated with the basal-like subtype, and had a 
similar molecular basis. Omics-based signatures were constructed to predict morphological 
features. The association of morphology transcriptome signatures with overall survival in 
oestrogen receptor (ER)-positive and ER-negative breast cancer was first assessed by use of the 
Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) dataset; signatures 
that remained prognostic in the METABRIC multivariate analysis were further evaluated in five 
additional datasets. The transcriptomic signature of poorly differentiated epithelial tubules was 
prognostic in ER-positive breast cancer. No signature was prognostic in ER-negative breast cancer. 
This study provided new insights into the molecular basis of breast cancer morphological 
phenotypes. The integration of morphological with molecular data has the potential to refine breast 
cancer classification, predict response to therapy, enhance our understanding of breast cancer 
biology, and improve clinical management. This work is publicly accessible at www.dx.ai/
tcga_breast.
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Introduction
Histopathological analysis of breast tumours plays a central role in the diagnosis of breast 
cancer. The assessment of histological type [e.g. invasive ductal carcinoma (IDC) or invasive 
lobular carcinoma (ILC)] and histological grade (a summary score of epithelial tubule 
formation, mitotic count, and nuclear pleomorphism) are reported to guide clinical 
management [1–4]. The microscopic assessment of tumour-infiltrating lymphocytes can 
predict improved response to chemotherapy and prognosis in erb-b2 receptor tyrosine kinase 
(HER2)-positive breast cancer [5–8]. Beyond these features, breast tumours show an array of 
other morphological features such as necrosis, the clinical significance of which is not well 
characterized.
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Breast cancer is a heterogeneous disease at both the morphological and molecular levels. 
The PAM50 molecular ‘intrinsic’ subtypes, luminal A, luminal B, HER2-enriched, basal-
like, and normal-like, have distinct biological properties, epidemiological risk factors, 
responses to therapy, and prognoses, and are associated with specific morphological features 
[9–13]. The normal-like subtype is highly variable and is not reproducibly defined [14]. 
Morphological and molecular data complement the characterization of breast cancer 
phenotypes. For example, basal-like tumours show high histological grade, necrosis, tumour-
infiltrating lymphocytes, and fibrotic foci, and are generally IDCs [15–19], whereas HER2-
enriched tumours show high histological grade, and may contain apocrine features and 
ductal carcinoma in situ (DCIS) [20,21].
Few studies have analysed the molecular characteristics of morphological features. These 
studies were limited by sample sizes (n = 57–212), and investigated one to three features 
with one or two types of molecular data [22–25]. The Genomic Grade Index (GGI; i.e. 
MapQuant Dx) is a transcriptomic signature constructed by integrating histological grade 
with gene expression, and is associated with oestrogen receptor (ER)-positive breast cancer 
prognosis [22]. GGI, like most first-generation prognostic signatures, is largely a measure of 
cellular proliferation [14,26,27]. The molecular bases of histological grade components, 
nuclear pleomorphism, epithelial tubule formation, and mitotic count, as well as other breast 
tumour morphological features, remain unknown.
This study aimed to comprehensively elucidate the molecular basis of breast cancer 
morphological phenotypes by integrating genomic, transcriptomic and proteomic data with 
morphological features, and to determine whether morphology transcriptomic signatures 
were prognostic in ER-positive or ER-negative breast cancer. To achieve this, a team of 15 
international breast cancer pathology experts provided detailed histopathological annotation 
for 850 invasive breast cancer cases in The Cancer Genome Atlas (TCGA). After we had 
integrated the consensus assessments of 11 morphological features with TCGA’s molecular 
profiles, we identified genomic, transcriptomic and proteomic data associated with 
morphological features. Next, omics-based signatures representative of morphological 
features were constructed, and the prognostic value of each signature with overall survival 
was assessed by use of the Molecular Taxonomy of Breast Cancer International Consortium 
(METABRIC) database [28]. Signature(s) that remained prognostic in the METABRIC 
multivariate analysis were further evaluated in five additional datasets.
Materials and methods
Images and molecular data
TCGA data generation and processing were performed as previously described; samples 
were obtained from patients with appropriate consent from institutional review boards [29]. 
TCGA invasive breast cancer (n = 850) images were assessed via http://
cancer.digitalslidearchive.net/[30]. Molecular profiles were retrieved (http://
cancergenome.nih.gov/): RNAseq gene expression (Illumina HiSeq RNASeqV2 Level 
3.1.9.0); DNA methylation subtypes 1, 2, 3, 4 and 5 (Illumina Infinium DNA chips); 
microRNA subtypes 1, 2, 3, 4, 5, 6 and 7 (Illumina sequencing); and reverse-phase protein 
assay (RPPA) subtypes basal, HER2-enriched, luminal A, luminal A/B, ReacI, ReacII and 
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‘X’ (MD Anderson RPPA Core Facility). PAM50 classification and PAM50 proliferation 
score were computed [9,31,32].
Genomic alterations implicated in breast cancer (43 somatic mutations, 45 amplifications, 62 
deletions, and six multiple alterations, e.g. mutation and amplification) identified with 
Mutation Significance version 2 [33] and Genomic Identification of Significant Targets in 
Cancer [34] were retrieved from cBioPortal for Cancer Genomics [31]. Of a total of 156 
genomic alterations, 127 genomic alterations were assessed in this study after exclusion of 
multiple alterations (n = 6) and rare genomic alterations that occurred in fewer than five 
cases (n = 23). These were excluded to allow separate analyses of mutation, amplification, 
and deletion, and reduce spurious findings.
Histopathology morphological assessment
Cases were randomly assigned to the pathologists, and images were graded by use of an 
electronic scoring sheet adapted from the College of American Pathologists’ protocol for 
invasive breast examination [35] (supplementary material, Figure S1A). For routine clinical 
features such as histological type, histological grade (nuclear pleomorphism, mitotic count, 
and epithelial tubule formation), lobular carcinoma in situ (LCIS), and DCIS, the 
pathologists used criteria applied in clinical practice. For features not commonly assessed in 
clinical practice, including stromal inflammation, necrosis, the proportion of cancerous 
epithelium in the invasive portion by area (i.e. epithelial area), lymphovascular invasion, 
stromal central fibrotic foci, and apocrine features, the pathologists carried out conference 
calls to discuss the grading criteria, and circulated images for scoring. Images with high 
consensus diagnoses were circulated as examples for grading. Supplementary material, 
Figure S1B shows an annotated scoring sheet with additional pathological scoring criteria 
and details.
To define the final histological type, information from pathology reports and the pathology 
review committee were integrated [31]. Pathology assessments were converted to integer 
scores. For the proportion of cancerous epithelium, in cases with discordance, discordant 
scores were resolved by taking the minimum value. For other morphological features, if the 
most frequent feature value in the dataset was the maximum of the possible feature values, 
discordant scores were resolved by taking the minimum value; otherwise, the maximum 
value was used. This was done to obtain an even distribution of the scores in the final 
dataset. Table 1 shows the morphological features, and their grading categories and 
frequencies.
Inter-rater reliability
Inter-rater reliability was assessed for each morphological feature where cases were graded 
(using the categories shown in Table 1) by at least two pathologists. Inter-rater reliability 
was calculated according to Krippendorff’s alpha [36] (irr, version 0.84; R, version 3.2.1) 
with bootstrapping (100 iterations), and average percentage agreement.
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Subsequent exclusion of histological type and re-stratification of morphological features 
into binary groups
The molecular characterization of histological types was reported separately, and we 
demonstrated that histological type represents a morphological continuum with a significant 
proportion of cases with morphological features of both ductal and lobular cancers [31]. 
Thus, we decided to include the full range of histological types in this article to enable the 
robust identification of molecular profiles and signatures associated with the remaining 11 
morphological phenotypes across all types of invasive breast cancer. To reduce the 
complexity and to increase statistical power, morphological features were re-stratified into 
binary categories to determine the association of each morphological feature with a type of 
molecular data (Table 2). For example, we investigated the association of TP53 mutation in 
tumours with marked nuclear pleomorphism as compared with tumours with small/moderate 
nuclear pleomorphism, or genes differentially expressed in tumours with DCIS as compared 
with tumours without DCIS. All tests of statistical significance were two-sided. Statistical 
significance was achieved when the p-value was <0.05 or the false discovery rate (FDR) was 
<0.05.
Determining the association of morphological features with molecular profiles
Genomic data—The univariate associations of genomic alteration and DNA methylation 
subtype with morphological features was determined with a chi-square test with Bonferroni 
adjustment, and Fisher’s exact test with Benjamini–Hochberg multiple testing corrections, 
respectively.
Transcriptomic data—The associations of PAM50 and microRNA subtypes, PAM50 
proliferation score, differential gene expression and gene sets/pathways with morphological 
features were determined with a chi-square test with Bonferroni’s adjustment, Wilcoxon’s 
test, limmavoom with the Benjamini–Hochberg correction (version 3.22.1) [37], and piano 
(version 1.6.2) [38], respectively.
Differential gene expression (n = 15 398) was determined in all cases (i.e. overall, n = 826) 
and within each PAM50 subtype, except in the normal-like subtype (excluded because of 
small sample size, n = 24). Gene set enrichment analysis was performed with the C2 
Molecular Signatures Database, which includes gene sets from Reactome, BioCarta, and 
KEGG (version 4.0, n = 4646; www.broadinstitute.org/gsea/msigdb/). Gene sets that were 
distinctly upregulated or downregulated were reported.
Proteomic data—The association of RPPA subtype with morphological features was 
determined with a chi-square test with Bonferroni adjustment.
Constructing molecular signatures of morphological features
Elastic-net regularized generalized linear models (glm-net, version 2.0-2) [39] was used to 
construct molecular signatures of morphological features according to genomic alteration, 
transcriptomic or both types of data (genomic and transcriptomic). Model performances 
were assessed according to the cross-validated area under the receiver operator characteristic 
curve (ROC AUC). To determine which type of molecular data best predicted morphological 
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features, the ROC AUC of models built with genomic alterations, transcriptomic or both 
types of data were compared by use of a paired t-test.
Molecular signatures for histological grade were also constructed. A histological grade 
‘feature’ was created by summing the original scores of epithelial tubule formation, nuclear 
pleomorphism, and mitotic count. The summed scores (ranging from 3 to 9) were then 
stratified into low/medium histological grade (summed scores of 3–7) or high histological 
grade (summed scores of 8 or 9).
Transcriptomic signatures predicted morphological features with the highest ROC AUCs. 
Thus, morphology transcriptomic signatures were subjected to bootstrapping (1000 
iterations) to obtain 95% confidence intervals for gene coefficient estimates. Gene 
coefficients with 95% confidence intervals crossing zero were dropped from the signature. 
Gene set enrichment of each transcriptomic signature was performed with Gene Ontology 
Biological Processes summarized version (DAVID 6.7 [40]). Statistical significance was 
achieved when the FDR was <0.05.
Survival analyses performed with the METABRIC breast cancer dataset
To determine whether the morphological features’ transcriptomic signatures were prognostic 
for overall survival, these signatures were compared with established proliferation-based 
prognostic signatures (GGI [22], OncotypeDx [41], and MammaPrint [42]) and PAM50 
subtype determined from the METABRIC (n = 1992) dataset [28].
PAM50 subtypes for METABRIC were retrieved from Prat et al. [43]. Research-based 
classifications of GGI, OncotypeDx and MammaPrint for each woman were computed with 
genefu (version 3.1) [44]. Each morphological feature’s signature score was calculated by 
subtracting the average expression of genes with negative coefficients from the average 
expression of genes with positive coefficients.
A Cox proportional hazards model was used to assess the univariate associations of 
clinicopathological variables [age at cancer diagnosis, tumour size (in centimetres), node-
positive (spread to regional lymph nodes; yes/no) and clinical grade (1, 2 or 3)], PAM50, 
GGI, OncotypeDx, MammaPrint and morphology transcriptomic signatures with overall 
survival [45]. To ensure that the association of our morphology transcriptomic signatures 
with overall survival was not attributable to chance, the Significance Analysis of Prognostic 
Signatures (SAPS) algorithm was used to compare the prognostic utility of each morphology 
transcriptomic signature with ‘random’ transcriptomic signatures of similar size (saps, 
version 2.0.0) [46]. Hence, a morphology transcriptomic signature was only considered to be 
significant when the Cox model (Wald test) p-value was <0.05 and an absolute adjusted 
SAPS score of >1.3 was obtained.
Clinicopathological variables, PAM50, GGI, OncotypeDx and MammaPrint were considered 
to be significantly associated with survival when p-values were <0.05. Significant variables 
and/or signatures were subsequently evaluated in a multivariate model, adjusted by treatment 
(chemotherapy, hormone therapy, combined chemotherapy and hormone therapy, or 
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untreated). Analyses were performed separately in ER-positive and ER-negative breast 
cancers.
Meta-analysis of significant transcriptomic signatures
The transcriptomic signature of poorly differentiated epithelial tubules remained 
significantly prognostic in the METABRIC multivariate analysis among ER-positive women. 
This signature was further evaluated in a meta-analysis consisting of five ER-positive breast 
cancer gene expression datasets: CAL [47], PNC [48], NKI [42,49], TRANSBIG [50], and 
GSE25066 [51]. Each gene expression dataset was pre-processed with Weighted Gene Co-
Expression Network (version 1.47) [52], and annotated with lumi (version 2.20.2) [53]. 
These datasets were chosen because they had overall survival data or distant-relapse-free 
survival, clinical grade information, treatment information (for CAL, NKI, and GSE25066), 
and at least 10 000 annotated genes. The meta-analysis adjusted for clinical grade and 
treatment.
Website resource
Data are available at www.dx.ai/tcga_breast. Detailed methodologies are given in 
Supplementary materials and methods.
Results
Pathology morphological dataset and assessment of inter-rater reliability
From November 2011 to March 2014, 15 pathologists completed 1524 online scoring sheets: 
11 cases were reviewed >10 times, 15 cases were reviewed five to nine times, 357 cases 
were reviewed two to four times, and 467 cases were reviewed once. The annotations and 
frequencies of morphological assessments are shown in Table 1. The prevalence rates of 
IDC, ILC and special histological types were similar to those in previous reports (IDC, 50–
80%; ILC, 5–15%; special histological types, 1–15%). The proportion of mixed IDC/ILC 
cases (10.9%) in this study appear to be slightly higher than the 3–7% reported by a limited 
number of studies [54–59]. Supplementary material, Table S1A–D shows the frequencies 
stratified by PAM50 subtype for all cases, within IDCs, within ILCs or within special 
histological types. Raw annotation data are shown in supplementary material, Table S2. 
Inter-rater reliability was calculated for 383 cases that were reviewed at least twice. There 
was moderate agreement among pathologists, with percentage agreements ranging from 
78% (mitotic count) to 98% (LCIS) (Table 3).
Morphological features are associated with molecular data
Table 4 summarizes the associations of each morphological feature with various molecular 
data (details are shown in supplementary material, Table S3 and Figure S2). Differential 
gene expression was performed in all cases and within each PAM50 subtype, except in the 
normal-like subtype (supplementary material, Table S4A). Owing to small sample sizes, 
differential gene expression associated with the presence of LCIS was performed for all 
cases and within luminal A cases.
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Inflammation, necrosis, nuclear pleomorphism, and mitotic count
Inflammation, necrosis, marked nuclear pleomorphism and medium/high mitotic counts co-
occurred in the tumours and shared many genomic alterations (FDR of <0.05; Figure 1, 
Table 4). In the TCGA publication, DNA methylation subtypes 3 and 5 are enriched for 
luminal B and basal-like, respectively, whereas TCGA microRNA subtypes 4 and 5 are 
associated with basal-like [29]. Therefore, the presence of inflammation and necrosis, 
marked nuclear pleomorphism and medium/high mitotic counts are distinctly associated 
with the highly proliferative basal-like subtype (Table 4).
These four morphological features had 15 common upregulated genes involved in cellular 
proliferation (MYBL2, CHEK1, CENPA, MELK, MEMO1, NASP, RCC2, LTV1, and 
C1orf135) [60,61], MYC activation (CDCA7) [62–65], and DNA and RNA metabolism 
(PIF1, RBM17, AMD1, and RPIA). The function of C17orf96 is unknown. These four 
morphological features also had 13 common downregulated genes involved in membrane 
signalling (CBLN4, ELFN1, LTBP3, LRP10, TENC1, and TPCN1), including GTPase 
activity (RAPGEF3 and TBC1D13), transcription (CAMTA2, CRY2, and LOC653501), the 
cytoskeleton (KIF13B), and lysosome positioning (C10orf32). The plethora of differentially 
expressed genes associated with necrosis, marked nuclear pleomorphism and medium/high 
mitotic counts were enriched for proliferation gene sets, whereas the presence of stromal 
inflammation was enriched for inflammation gene signatures (FDR of <0.05; Figure 2; a 
detailed heatmap is shown in supplementary material, Figure S3). Collectively, molecular 
data suggest that tumorigenesis involving these four proliferative basal-like morphological 
features may be driven by MYB-regulated and MYC-regulated pathways, and, potentially in 
conjunction with TP53 pathways, in invasive breast cancer [60,66,67].
Epithelial tubule formation
Other studies reported the association of TP53, 8q24.21 (MYC), 19q12 (CCNE1), 20p13.2 
(ZNF217) and 9p21.3 (MTAP) with histologic grade [24,25]. However, when focussing on 
the individual components of histological grade, poorly differentiated epithelial tubules 
shared only a few molecular traits with medium/high mitotic counts and marked nuclear 
pleomorphism: TP53 mutation, high PAM50 proliferative score, basal-like subtype classified 
according to methylation, and microRNA data. The molecular traits of poorly differentiated 
epithelial tubules were common with those of LCIS (i.e. CDH1 mutation, PAM50 luminal A 
subtype, and inflammation gene sets), although there was no correlation between the two 
morphological features (supplementary material, Table S3B). P2RY11, which encodes a G-
protein-coupled receptor activated by extracellular adenosine and uridine [68], was the top 
differentially expressed gene (2.3-fold increase) in tumours with poorly differentiated 
epithelial tubules as compared with well-differentiated/moderately differentiated epithelial 
tubules (supplementary material, Table S4B). The role of P2RY11 in breast tissue remains 
unknown, and could be evaluated as a potential pharmacological target.
LCIS
LCISs are precursor lesions for ILCs, defined by the hallmark CDH1 loss-of-function 
mutation, and are almost exclusive to luminal A tumours [31,69]. Regardless of histological 
type, the presence of LCIS was also associated with DNA methylation subtype 1, 
Heng et al. Page 8
J Pathol. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
downregulation of proliferation gene sets, and enrichment for cytokines/immune-signalling 
pathways (despite not being associated with the presence of morphological inflammation). 
The expression of HMGCS2, a breast apocrine carcinoma marker involved in the anabolic 
ketogenesis pathway, was increased by 8.6-fold in tumours with LCIS (supplementary 
material, Table S4B) [70]. Other top-ranking upregulated genes were those involved in 
inflammation (GP2 and C7) [71], alcohol metabolism (ADH1B), fat metabolism (ADIPOQ) 
[72,73], transcription (TFAP2B), transmembrane proteins (TMEM132C and SLC7A4), and 
genes with unknown function (TFF1 and TUSC5) [74,75]. At the same time, the mRNA 
expression levels of extracellular matrix proteins (MMP1, CDH1, EPYC, COL11A1, 
HAPLN1, and IBSP) were significantly lower. Thus, APIPOQ and HMGCS2 
overexpression suggest that the manifestation of LCIS may reflect abnormal hormone and 
fatty acid levels in the breast tissues, impaired fatty acid oxidation, and mitochondrial 
dysfunction [76,77]. Mitochondrial dysfunction can lead to inflammation, tumorigenesis, 
dysregulation of cell–cell adhesion, discohesive morphology, and invasion [76,78–81]. 
These characteristics of mitochondrial dysregulation are supported by our differential gene 
expression analyses. It would also be interesting to investigate the association of lifestyle 
factors such as obesity or alcohol consumption with LCIS or histological type [72,82,83].
DCIS
The co-existence of DCIS with prominent features (i.e. strong molecular profiles) such as 
marked nuclear pleomorphism and poorly differentiated epithelial tubules may have masked 
our ability to decipher the molecular basis of DCIS (supplementary material, Table S3B). 
DCIS was associated with 40 differentially expressed genes, and was enriched for 
proliferation and cell–cell junction pathways (supplementary material, Figure S3). The top-
ranking upregulated genes in breast cancers associated with DCIS were those encoding 
epithelial proteins (CALML3, ANXA8L1, and ANXA8) [84,85], extracellular matrix 
proteins (KRT14, KRT6B, KRT17, and MMP10) [86], desmosomes (DSG3 and DSC3) that 
connect adjacent myoepithelial cells [87], and proteins involved in myoepithelial cell 
differentiation (ACTA1) [88] and CCL21-related chemotaxis resulting in epithelial–
mesenchymal transition and metastasis [89–91]. These results support reports that the 
progression of DCIS to invasive breast cancer is influenced by changes in 
microenvironmental factors, especially in myoepithelial cells [87,92]. Proliferating 
cancerous ductal cells exert pressure against the myoepithelial cells and basement 
membrane. When the myoepithelial cells cannot sustain the pressure and rate of basement 
membrane turnover, they lose their cell–cell adhesion capabilities and allow the cancerous 
cells to invade into the surrounding tissues [87]. The 11 downregulated genes in breast 
cancers associated with DCIS are newly associated with breast cancer [cytoskeleton-related 
(HOOK2 and ARHGEF18), mitochondrial iron–sulphur cluster assembly pathway 
(C1orf69), gene regulation (MAFG and WDR37), GTPase activity (TBC1D13 and RAB43), 
lipid synthesis (CLN8), and neuronal components (PRX, LOC100130093 and OPA3); 
supplementary material, Table S4B]. Their involvement in DCIS and/or invasive breast 
cancer warrants further elucidation.
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Apocrine features
This is the first study to characterize the molecular basis of apocrine features (Table 4). 
Upregulated genes and enriched pathways associated with marked apocrine features include 
increased lipid and membrane transport (ABCC2, ABCA12, ABCC11, HAPLN1, FIBCD1, 
and FAM155B), lipid and/or cell metabolism (DHRS2, HGD, IYD, and HHIPL2), apoptotic, 
diabetes and cholesterol pathways. Downregulated genes and pathways with marked 
apocrine features were those encoding gastropeptides (NPYIR and PI16) and serine 
peptidase (KLK11), and those involved in alcohol/drug metabolism (ADH1B and 
CYP4F22), secretion (AQP5), the extracellular matrix (HAPLN1), and cytokine signalling 
(C7 and DARC). These genes have been investigated as markers of proliferation or 
metastasis [93–99], breast cancer risk [100], prognosis [101,102], and response to therapy 
[103–106]. Our work suggests that drug resistance may occur in tumours with marked 
apocrine features with overexpression of ATP-binding cassette transporter mRNA, and new 
drugs targeting aquaporin water channels may not work in these tumours [103,107].
Lymphovascular invasion and fibrotic foci
Neither genomic alteration nor PAM50 subtype was associated with the presence of 
lymphovascular invasion [25], fibrotic foci, or a high proportion of cancerous epithelium. 
Interleukin-12-related and integrin-related neutrophil pathways and extracellular matrix 
organization gene sets were downregulated in the presence of lymphovascular invasion. The 
presence of fibrotic foci was linked to upregulated integrin and extracellular matrix 
organization gene sets, and down-regulated inflammation gene sets. The lack of distinct 
molecular profiles for lymphovascular invasion and fibrotic foci may be attributable to their 
low frequencies, and suggests that these features remain largely morphological.
Transcriptomic signatures of morphological features
Genomic alterations, gene expression or both data types were used to construct signatures of 
morphological features. The ROC AUCs of multivariate models built with transcriptomic 
and combined data outperformed models constructed with genomic alterations (p ≤ 0.001; 
supplementary material, Table S5A). There was no difference in the ROC AUCs between 
transcriptomic and combined data, indicating that the addition of genomic alteration data did 
not enhance the performance of transcriptomic signatures in predicting morphological 
features (p = 0.139; supplementary material, Table S5B). Thus, only transcriptomic 
signatures were subjected to bootstrapping and further explored. The transcriptomic 
signatures of morphological features ranged from one gene (LRRC32) for the proportion of 
cancerous epithelium to 110 genes for poorly differentiated epithelial tubules 
(supplementary material, Table S5C, D).
The stromal inflammation signature is enriched for the suppression of T-cell activation, 
driven by its strongest (positive) coefficient, CTLA4. The increase in the level of CTLA4 in 
breast cancer prevents the anti-tumour T-cell response [108]. Its monoclonal antibody, anti-
CTLA4, when used in synergy with other therapeutic agents (e.g. trastuzumab), blocks 
immune checkpoints, and induces anti-tumour immunity, resulting in tumour regression in 
preclinical (HER2) breast cancer models [109–112]. However, the blocking of immune 
checkpoints with antibodies against programmed cell death protein 1 and its ligand is more 
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effective than using anti-CTLA4 [109,113,114]. Future work could evaluate whether this 
inflammation signature can identify women who may benefit from anti-CTLA4 therapy, as 
well as investigating how CTLA4 contributes to tumour immunity [115].
Signatures for medium/high mitotic count, marked nuclear pleomorphism and high 
histological grade were enriched for cell proliferation, further confirming that these features 
are proliferation-related (supplementary material, Table S5E). No enrichment was obtained 
for other signatures.
The epithelial tubule formation transcriptomic signature was prognostic in ER-positive 
breast cancer
In METABRIC ER-positive women (n = 1494), age at cancer diagnosis, tumour size, node-
positive status and the transcriptomic signature for poorly differentiated epithelial tubules 
remained prognostic in the multivariate model (p < 0.05; Table 5). In ER-negative women (n 
= 434), no feature was prognostic in the multivariate model.
The transcriptomic signature for poorly differentiated epithelial tubules in ER-positive 
women was further evaluated in a meta-analysis across five publicly available gene 
expression datasets (Figure). The summary hazard ratio was 1.94 (95% confidence interval 
1.51–2.38).
The epithelial tubule formation transcriptomic signature is distinct and least correlated 
with proliferation
The transcriptomic signature for poorly differentiated epithelial tubules was distinct from the 
signatures for medium/high mitotic count, marked nuclear pleomorphism, and high 
histological grade (Figure 4). To determine whether the transcriptomic signature for poorly 
differentiated epithelial tubules was the least correlated with proliferation, the PAM50 
proliferation score for each woman in the METABRIC dataset was calculated and correlated 
with the transcriptomic signature scores of nuclear pleomorphism, mitotic count, and 
epithelial tubule formation. PAM50 proliferation scores were more highly correlated with 
medium/high mitotic count [Spearman’s rho = 0.878 (ER-positive) and Spearman’s rho = 
0.919 (ER-negative)] and marked nuclear pleomorphism (rho = 0.852 and rho = 0.904) than 
with poorly differentiated epithelial tubules (rho = 0.351 and rho = 0.616) in ER-positive 
and ER-negative invasive breast cancers (p < 0.001).
Discussion
Little is known about the molecular characteristics of various morphological features in 
invasive breast cancer. We comprehensively unravelled the molecular portraits of breast 
cancer histopathological phenotypes by bridging histopathological annotations with the 
molecular profiles in the TCGA database. This article represents the largest cross-section of 
cases and pathologists to examine breast cancer histopathological phenotypes to date. Our 
data support the central role of proliferation driving histological grade. Inflammation, 
necrosis, medium/high mitotic count and marked nuclear pleomorphism frequently co-exist 
in breast tumours, are associated with basal-like subtypes, and have similar molecular bases. 
LCIS has a distinct molecular profile that may be linked to mitochondrial dysfunction, 
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whereas genes that are differentially expressed in DCIS are intimately associated with 
myoepithelial cells. Lymphovascular invasion and fibrotic foci are mainly morphological, 
with few significant molecular traits.
Some morphological features harbour molecular traits that may confer drug resistance or 
serve as pharmacological targets. Our signatures can act as surrogate representation of 
morphological features, enabling future studies to link the signatures to response to therapy, 
with the long-term aim of improving clinical management. Personalized or refined breast 
cancer classification can be achieved by combining the observation of morphological 
features with molecular and immunohistochemistry data. Collectively, this study provides 
new insights into the molecular basis of breast cancer morphological phenotypes, and could 
potentially facilitate the future development of diagnostic and prognostic tools for breast 
cancer.
Most databases, including METABRIC, usually provide information on histological grade 
but not its components such as epithelial tubule formation. We were unable to directly 
determine whether the pathological measure of epithelial tubules is independently 
prognostic, or whether our transcriptomic signature of epithelial tubule formation adds 
prognostic information or is superior to pathological assessment. However, if high 
histological grade can function as a surrogate for poorly differentiated epithelial tubules, our 
multivariate analyses show that the epithelial tubule formation signature is more prognostic 
than clinical histological grade, and indirectly demonstrate that our signature adds 
prognostic information for ER-positive breast cancer. Nevertheless, prognostic signatures for 
ER-positive breast cancer are well established [22,41,42], and more research is needed to 
discover clinically useful prognostic signatures for ER-negative breast cancer.
At the molecular level, epithelial tubule formation is least similar to mitotic count and 
nuclear pleomorphism, and shares traits with LCIS and inflammation. The transcriptomic 
signature for poorly differentiated epithelial tubules is distinct from high histological grade, 
but not significantly enriched for any gene sets. The signature’s genes are involved in 
proliferation, mitochondrial metabolism, membrane signalling, cellular adhesion, oxidative 
stress, extracellular matrix organization, and inflammation. These gene functions are a mix 
of selective molecular traits associated with medium/high mitotic count, marked nuclear 
pleomorphism, LCIS, and inflammation. We speculate that our transcriptomic signature for 
poorly differentiated epithelial tubules is unique and prognostically superior, because it 
contains genes that represent a wide range of tumour biology.
The failure to detect any association of DCIS, fibrotic foci or apocrine features with PAM50 
subtypes may be attributable to our study utilizing PAM50 classification by molecular data 
instead of immunohistochemistry, using different grading criteria, and investigating these 
features within tumours of invasive breast cancer [116–119]. Our transcriptomic signature 
for fibrotic foci was not prognostic, despite previous studies reporting that IDCs or luminal 
B tumours with fibrotic foci have a poorer prognosis [120,121]. The relevance of fibrotic 
foci as a prognostic factor requires further investigation, which should take into 
consideration its size, breast cancer histological type, and PAM50 classification.
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Fourteen TCGA cases were inadequate for scoring, owing to poor image quality or 
insufficient invasive cancer being present. Despite adherence to clinical definitions or agreed 
consensus scoring criteria, our histopathological analyses may be influenced by the variation 
in histology quality and the use of images instead of slides for scoring. For example, the 
high-power field used to count mitotic bodies at the highest magnification (×40) on a web 
browser is infuenced by computer monitor size (hence, the high-power field for each 
pathologist varies) and the difficulty in distinguishing between mitotic figures from 
pynknotic nuclei, owing to the lack of a Z-axis. The pathologists used their best judgement 
in counting cells in mitosis. However, the mitotic count (as it was scored) was highly 
concordant with the PAM50 proliferation score and enrichment for proliferation gene sets in 
this study, signifying that both mitotic count and gene expression were adequately tracking 
proliferation. Another limitation of this study is that we focused exclusively on a set of 
known morphological features that could be scored manually by experienced breast 
pathologists. It is likely that there are additional morphological patterns (e.g. various types 
of stromal reaction pattern) beyond those included in our study that are biologically 
important and will provide additional insights into the molecular underpinnings of breast 
cancer pathology.
In conclusion, breast tumour pathological phenotypes are driven by distinct underlying sets 
of molecular alterations. The integration of morphological with molecular data has great 
potential to refine breast cancer classification, predict response to therapy, enhance our 
understanding of breast cancer biology, and improve clinical management.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Heatmap and unsupervised hierarchical clustering of the 38 significant genomic alterations 
and 11 morphological features based on the degree and direction of the associations. 
Inflammation and necrosis, marked nuclear pleomorphism and medium/high mitotic counts 
are clustered together, as they share many common genomic alterations.
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Figure 2. 
Heatmap summarizing the FDRs of 485 significant pathways and unsupervised hierarchical 
clustering of morphological features. Features are clustered into two groups characterized 
mainly by proliferation and inflammation. Detailed pathways are presented in 
supplementary material, Figure S3. The proliferation cluster had increased cell proliferation 
and metabolism, and decreased inflammation and membrane receptor signalling. The 
inflammation cluster comprised largely immune-related signatures.
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Figure 3. 
The prognostic significance of the transcriptomic signature for poorly differentiated 
epithelial tubules in ER-positive women was further validated in a meta-analysis across five 
cohorts. *The endpoint for GSE25066 is distant relapse-free survival; the endpoints for all 
other datasets are overall survival. The summary hazard ratio estimate is a weighted average. 
Weights are the reciprocal of the estimated variance (square of standard error for the 
analysis). CI, confidence interval.
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Figure 4. 
(A) There were 17 overlapping genes between the transcriptomic signatures for medium/
high mitotic count and marked nuclear pleomorphism, whereas genes predictive of poorly 
differentiated epithelial tubules were distinct. (B) Most of the genes in the transcriptomic 
signature for high histological grade were common to the signatures for medium/high 
mitotic count and marked nuclear pleomorphism, but were distinct from of poorly 
differentiated epithelial tubules.
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Table 2
The re-stratification of the 11 morphological features into binary grading levels for integration with molecular 
data
Morphological features Binary categories
Histological grade
 Epithelial tubule formation >10% (well/moderately differentiated)
<10% (poorly differentiated)
 Nuclear pleomorphism Small regular nuclei/moderate increase in size
Moderate to marked variation in size
 Mitotic count 0–5 per 10 HPFs (low)
>6 per 10 HPFs (medium/high)
In situ cancer
 DCIS Present or absent
 LCIS Present or absent
Other features
 Stromal inflammation Present or absent
 Necrosis Present or absent
 % Cancerous epithelium <75% (low/moderate)
>75% (high)
 Apocrine features Absent/1–50% (minimum/moderate)
>50% (marked)
 Lymphovascular invasion Present or absent
 Stromal central fibrotic focus Present or absent
DCIS, ductal carcinoma in situ; HPF, high-power field; LCIS, lobular carcinoma in situ.
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Table 3
Inter-rater reliability on cases graded by at least two pathologists and Krippendorff’s alpha with bootstrap 
resampling and percentage agreement; each morphological feature’s grading categories are shown in Table 1
Morphological feature Cases (n) Krippendorff’s alpha
Krippendorff’s alpha with 
bootstrap resampling (95% 
confidence interval) Agreement (%)
Histological type 358 0.471 0.472 (0.402–0.532) 85.6
Histological grade
 Epithelial tubule formation 316 0.544 0.547 (0.463–0.621) 87.4
 Nuclear pleomorphism 318 0.522 0.520 (0.457–0.590) 80.8
 Mitotic count 311 0.488 0.493 (0.421–0.576) 77.7
In situ cancer
 Ductal carcinoma in situ 317 0.526 0.521 (0.451–0.592) 89.0
 Lobular carcinoma in situ 317 0.298 0.303 (0.088–0.507) 97.5
Other features
 Stromal inflammation 315 0.544 0.534 (0.442–0.593) 89.8
 Necrosis 317 0.591 0.581 (0.474–0.669) 90.6
 Proportion of cancerous epithelium in invasive 
portion by area (excluding areas of necrosis)
312 0.472 0.467 (0.387–0.538) 79.2
 Apocrine features 314 0.164 0.189 (0.076–0.318) 90.3
 Lymphovascular invasion 312 0.423 0.413 (0.327–0.515) 90.1
 Stromal central fibrotic focus 311 0.256 0.262 (0.155–0.367) 82.7
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Table 4
An overview of molecular data significantly associated with morphological features
Stromal inflammation, necrosis, nuclear pleomorphism, and mitotic count
The presence of necrosis and inflammation, a medium/high mitotic count and marked nuclear pleomorphism was associated with the following:
• TP53 loss-of-function mutation, and chr12p13.3, ch8q24.21 (MYC) and chr3q26.3 amplifications
• PAM50 basal-like subtype, higher PAM50 proliferation score
• DNA methylation subtypes 4 and 5, microRNA subtype 4 (these subtypes are linked to basal-like subtypes [29])
• RPPA (basal-like subtype)
• Presence of necrosis, medium/high mitotic count and marked nuclear pleomorphism were enriched for proliferation gene sets
• Presence of inflammation was enriched for inflammation gene setsIn general, these four features are linked to Basal-like subtypes 
and have similar molecular bases
Epithelial tubule formation
Poorly differentiated epithelial tubules were associated with:
• TP53 and CDH1 loss-of-function mutations
• chr12p13.3, ch8q24.21 (MYC) and chr3q26.3 amplifications
• PAM50 luminal A subtype, higher PAM50 proliferation score
• DNA methylation subtypes 4 and 5, microRNA subtype 4
• Enrichment for inflammation gene setsPoorly differentiated epithelial tubules share selective molecular traits with medium/high 
mitotic count, marked nuclear pleomorphism, and LCIS
LCIS
The presence of LCIS was associated with:
• CDH1 loss-of-function mutation
• PAM50 luminal A subtype, lower PAM50 proliferation score
• DNA methylation subtype 1
• Downregulation of proliferation gene setsThe molecular profile of LCIS may be linked to mitochondrial dysfunction
DCIS
Tumours with DCIS were enriched for proliferation gene sets
Upregulated genes in DCIS are linked to the breast microenvironment, especially myoepithelial cells
Apocrine features
The presence of marked apocrine features was associated with:
• chr20q13.2 and chr17q11.2.q12.17q21.1 amplifications
• Enriched gene sets linked to lipid and membrane transport, and lipid and/or cell metabolism
• Downregulated alcohol/drug metabolism gene sets and cytokine signalling
• Tumours with marked apocrine features overexpress ATP-binding cassette transporters
Lymphovascular invasion
The lymphovascular invasion feature remains mainly morphological but was also associated with:
• RPPA basal subtype
• Downregulation of IL-12 and integrin-related neutrophil pathways, and extracellular matrix organization gene sets
Stromal central fibrotic foci
The presence of fibrotic foci remains mainly morphological
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Fibrotic focus was not associated with any gene, but showed downregulated inflammation gene sets
Proportion of cancerous epithelium in invasive portion by area (excluding areas of necrosis)
A high proportion of cancerous epithelium was associated with:
• PAM50 luminal A, higher PAM50 proliferation score
• RPPA luminal A/B subtype
chr, chromosome; DCIS, ductal carcinoma in situ; IL, interleukin; LCIS, lobular carcinoma in situ.
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